Biomarkers of Engineered Cell Viability After Infusion: Scientific and Clinical Perspectives

Abstract

The infusion of engineered cellular therapies, such as chimeric antigen receptor (CAR) T cells and other genetically modified immune cells, has revolutionized the management of various malignancies and some non-malignant diseases. However, the assessment of infused cell viability post-administration remains a fundamental challenge that impacts clinical outcomes, therapeutic efficacy, and safety. This review examines key biomarkers currently available and under investigation for monitoring engineered cell viability after infusion. Drawing on recent PubMed-indexed literature, we discuss the underlying mechanisms, clinical relevance, and practical implications of these biomarkers, providing a comprehensive resource for clinicians and researchers involved in cellular therapy.

Introduction

Engineered cell therapies have emerged as a cornerstone in the treatment of hematologic malignancies, select solid tumors, and autoimmune disorders. The viability of infused cells directly correlates with clinical response, persistence, and risk of adverse events such as cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). While manufacturing processes ensure product quality prior to infusion, post-infusion viability monitoring is critical for optimizing patient outcomes. Biomarkers that accurately reflect the fate, functionality, and survival of these cells are essential for guiding clinical decisions and advancing therapeutic protocols.

Epidemiology / Disease Burden

The global application of engineered cell therapies is expanding rapidly, particularly in hematologic oncology. CAR T-cell therapies have demonstrated unprecedented remission rates in relapsed or refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The burden of disease addressed by these therapies is significant, with high relapse rates and limited options for patients who fail standard treatments. The rise in cellular therapy clinical trials and approvals underscores the urgent need for robust post-infusion monitoring strategies, including viable cell tracking, to ensure sustained remission and to mitigate complications.

Pathophysiology

Engineered cells, such as CAR T cells, are subject to unique stressors upon infusion, including immune-mediated clearance, exposure to cytokine-rich environments, and interactions with tumor or host microenvironments. Viability loss may result from apoptosis, necrosis, exhaustion, or target-mediated toxicity. The persistence and functional competence of these cells underpin their therapeutic potential. Pathophysiological factors influencing viability include host immune rejection, antigen escape, and microenvironmental suppressive signals. Understanding these mechanisms is essential for interpreting biomarker data and guiding therapeutic interventions.

Risk Factors

Several factors impact the post-infusion viability of engineered cells. Host-related risks include immunosuppression, prior therapies, and baseline inflammatory status. Product-related issues such as transduction efficiency, cell phenotype, and manufacturing quality control also contribute. Additionally, the tumor microenvironment can exert inhibitory effects via immunosuppressive cytokines or checkpoint ligands, reducing cell persistence. Identification of risk factors enables stratification of patients and tailoring of monitoring protocols, enhancing the clinical utility of post-infusion biomarkers.

Clinical Features

Clinically, the viability of infused engineered cells manifests as the degree and duration of therapeutic response, incidence of CRS, neurotoxicity, and long-term disease control. Early loss of viability may present as poor initial response or early relapse, while excessive persistence can contribute to prolonged cytopenias or autoimmunity. Monitoring clinical correlates alongside laboratory biomarkers allows for comprehensive assessment and timely intervention, improving patient safety and efficacy outcomes.

Diagnosis

Current diagnostic tools for assessing engineered cell viability include flow cytometry, quantitative PCR (qPCR) for transgene detection, and functional assays measuring cytokine release or cytotoxicity. Flow cytometry allows for the detection of infused cells using unique markers such as CAR constructs or lentiviral transgenes. qPCR quantifies the persistence of genetically modified sequences, offering high sensitivity. Emerging techniques such as single-cell RNA sequencing and digital droplet PCR provide deeper insights into cell fate and functional status. Serum biomarkers, such as cell-free DNA and specific cytokine patterns, are being explored as non-invasive indicators of cell viability and activity.

Treatment & Management

Management strategies following cell infusion are closely linked to viability assessment. In cases of low persistence, strategies such as cytokine support (e.g., IL-2, IL-15), checkpoint inhibition, or repeat infusion may be considered. Conversely, excessive viable cell expansion requires prompt intervention to manage toxicities using corticosteroids, tocilizumab, or other immunosuppressants. Real-time biomarker monitoring informs these decisions, enabling dynamic adjustment of therapeutic approaches to maximize benefit and minimize harm.

Recent Advances / Emerging Therapies

Recent advances in biomarker discovery are transforming post-infusion monitoring. Novel imaging modalities, such as PET tracers targeting engineered cell-specific epitopes, allow for in vivo visualization of cell distribution and viability. High-throughput omics technologies facilitate identification of gene expression signatures associated with persistence and function. Synthetic biomarkers, including suicide genes and reporter constructs, are being engineered into cell products to provide real-time, quantifiable readouts of viability. These developments promise to enhance precision in cell therapy monitoring and to support adaptive clinical management.

Guideline Recommendations

Leading guidelines from organizations such as the American Society for Transplantation and Cellular Therapy (ASTCT) and the European Society for Blood and Marrow Transplantation (EBMT) underscore the importance of standardized cell monitoring post-infusion. Recommendations include routine flow cytometric enumeration, molecular quantification of transgene copies, and serial assessment of clinical and laboratory parameters. Implementation of validated biomarker protocols is advised to ensure consistency across clinical centers and to facilitate data comparison in research settings.

Conclusion

Biomarkers of engineered cell viability after infusion are central to the successful implementation of cellular therapies. Integration of robust, sensitive, and clinically actionable biomarkers enables timely detection of therapeutic efficacy, early identification of complications, and informed management decisions. Continued research into novel biomarkers and their clinical validation will further refine post-infusion monitoring, ultimately improving patient outcomes and advancing the field of engineered cell therapeutics.